ReviewExpert opinion on drug safety2018
Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder.
Review in Expert opinion on drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Inhibition of the serotonin transporter and risk of heart valve disease: A systematic review and meta-analysis.European journal of pharmacology · 2026Pooled it
- Systematic Review of Binge Eating Rodent Models for Developing Novel or Repurposing Existing Pharmacotherapies.Biomolecules · 2023Pooled it
- Pooled it
- Bulimia nervosa.Nature reviews. Disease primers · 2026Review
- Approved and Pipeline Pharmacological Interventions for Eating Disorders (2010-2025): 15 Years of Progress (or Lack Thereof).CNS drugs · 2026Review
- Pharmacological management of binge eating disorder.The mental health clinician · 2025Article
- Clinical Intervention Strategies and Family Dynamics in Adolescent Eating Disorders: A Scoping Review for Enhancing Early Detection and Outcomes.Journal of clinical medicine · 2024Article
- The emerging role of glucagon-like peptide 1 in binge eating.The Journal of endocrinology · 2024Review
- Psychopharmacology Review for Eating Disorders Among Children, Adolescents, and Adults.Focus (American Psychiatric Publishing) · 2024Review
- Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.Obesity pillars · 2023Article
- Current Discoveries and Future Implications of Eating Disorders.International journal of environmental research and public health · 2023Review
- Pharmacotherapy, alternative and adjunctive therapies for eating disorders: findings from a rapid review.Journal of eating disorders · 2023Review
- Eating Disorders and Metabolic Diseases.International journal of environmental research and public health · 2023Review
- Stress, psychiatric disease, and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.Obesity pillars · 2022Article
- Psychopharmacologic Management of Eating Disorders.Current psychiatry reports · 2022Review
- Integrative Hedonic and Homeostatic Food Intake Regulation by the Central Nervous System: Insights from Neuroimaging.Brain sciences · 2022Review
- Neural Response to Low Energy and High Energy Foods in Bulimia Nervosa and Binge Eating Disorder: A Functional MRI Study.Frontiers in psychology · 2022Article
- Association Between DRD2 and DRD4 Polymorphisms and Eating Disorders in an Italian Population.Frontiers in nutrition · 2022Article
- Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.Neurology international · 2021Review
- A review of binge eating disorder and obesity.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionEating disorders represent a set of psychiatric illnesses with lifelong complications and high relapse rates. Individuals with eating disorders are often stigmatized and clinicians have a limited set of treatments options. Pharmacotherapy has the potential to improve long term compliance and patient commitment to treatment for eating disorders. AREAS COVERED: This review will examine the efficacy and safety profile of the FDA-approved medications for the treatment of bulimia nervosa (BN) and binge eating disorder (BED). This will include the evaluation of fluoxetine for BN, and lisdexamfetamine for BED. Safety information will be review from randomized control trials (RCT), open label trials, and case reports. EXPERT OPINION: Fluoxetine for BN and lisdexamfetamine for BED are relatively safe and well-tolerated. Despite these properties, these two medications represent a limited arsenal for the pharmacological treatment of eating disorders. Thus, more research-based strategies are needed to develop safe, effective, and more targeted therapies for eating disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.